EGLN1: The Potential Drug Target and Biomarker (G54583)

Target Name: EGLN1

NCBI ID: G54583

EGLN1

EGLN1: The Potential Drug Target and Biomarker

E GLN1 (E-cadherin-like gene 1) is a gene that encodes a protein known as EGLN1. EGLN1 is a member of the cadherin gene family, which is a group of transmembrane proteins that play a crucial role in cell-cell adhesion. EGLN1 is expressed in various tissues and has been implicated in several biological processes, including cell signaling, tissue repair, and regeneration.

The Importance of EGLN1 in Cancer

E GLN1 has been shown to be involved in several aspects of cancer development and progression. For example, EGLN1 has been shown to be overexpressed in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, EGLN1 has been shown to be a potential biomarker for cancer, as it has been found to be associated with cancer-related survival in various studies.

The Potential Role of EGLN1 as a Drug Target

E GLN1 has been identified as a potential drug target due to its involvement in several cellular processes that are relevant to cancer treatment. For example, EGLN1 has been shown to be involved in cell signaling, which is a crucial aspect of cancer growth and progression. Additionally, EGLN1 has been shown to be involved in the regulation of cell adhesion, which is a critical aspect of tissue repair and regeneration.

One potential approach to targeting EGLN1 as a drug target is to use small molecules that can modulate its activity. For example, several studies have shown that inhibitors of the EGLN1 protein can inhibit cancer cell growth and metastasis. Additionally, some studies have shown that inhibitors of EGLN1 can also enhance the effectiveness of certain cancer treatments, such as chemotherapy and radiation therapy.

The Potential Role of EGLN1 as a Biomarker

E GLN1 has also been shown to be a potential biomarker for cancer, as it has been found to be associated with cancer-related survival in various studies. For example, one study showed that patients who had EGLN1 positive tumors had a significantly shorter overall survival rate compared to those who had EGLN1 negative tumors. Additionally, another study showed that patients who had EGLN1 positive tumors had a higher risk of developing metastasis compared to those who had EGLN1 negative tumors.

The potential use of EGLN1 as a biomarker for cancer has implications for the development of new diagnostic tests and therapies. For example, if EGLN1 can be used as a biomarker for cancer, it may be possible to develop new diagnostic tests that can be used to detect cancer at an early stage. Additionally, if EGLN1 can be used as a drug target, it may be possible to develop new treatments for cancer that target EGLN1.

Conclusion

E GLN1 is a gene that encodes a protein that is involved in several important cellular processes that are relevant to cancer development and progression. The potential use of E GLN1 as a drug target and biomarker suggests that it may be a valuable target for cancer treatment. Further research is needed to fully understand the role of E GLN1 in cancer and to develop new treatments based on its potential as a drug target and biomarker.

Protein Name: Egl-9 Family Hypoxia Inducible Factor 1

Functions: Cellular oxygen sensor that catalyzes, under normoxic conditions, the post-translational formation of 4-hydroxyproline in hypoxia-inducible factor (HIF) alpha proteins. Hydroxylates a specific proline found in each of the oxygen-dependent degradation (ODD) domains (N-terminal, NODD, and C-terminal, CODD) of HIF1A. Also hydroxylates HIF2A. Has a preference for the CODD site for both HIF1A and HIF1B. Hydroxylated HIFs are then targeted for proteasomal degradation via the von Hippel-Lindau ubiquitination complex. Under hypoxic conditions, the hydroxylation reaction is attenuated allowing HIFs to escape degradation resulting in their translocation to the nucleus, heterodimerization with HIF1B, and increased expression of hypoxy-inducible genes. EGLN1 is the most important isozyme under normoxia and, through regulating the stability of HIF1, involved in various hypoxia-influenced processes such as angiogenesis in retinal and cardiac functionality. Target proteins are preferentially recognized via a LXXLAP motif

The "EGLN1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EGLN1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets